DCF Advisers LLC Takes $715,000 Position in Zenas BioPharma, Inc. $ZBIO

DCF Advisers LLC bought a new position in shares of Zenas BioPharma, Inc. (NASDAQ:ZBIO) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 28,184 shares of the company’s stock, valued at approximately $715,000.

Other institutional investors have also modified their holdings of the company. Quarry LP boosted its holdings in Zenas BioPharma by 34.5% in the third quarter. Quarry LP now owns 1,134 shares of the company’s stock valued at $25,000 after purchasing an additional 291 shares during the last quarter. Russell Investments Group Ltd. purchased a new stake in Zenas BioPharma during the 3rd quarter worth approximately $30,000. BNP Paribas Financial Markets increased its holdings in Zenas BioPharma by 120.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock worth $70,000 after purchasing an additional 1,716 shares during the last quarter. CWM LLC raised its position in shares of Zenas BioPharma by 48.3% in the 4th quarter. CWM LLC now owns 2,178 shares of the company’s stock valued at $79,000 after purchasing an additional 709 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Zenas BioPharma in the 4th quarter valued at approximately $95,000.

Zenas BioPharma Price Performance

Shares of NASDAQ ZBIO opened at $31.25 on Thursday. Zenas BioPharma, Inc. has a 1-year low of $13.50 and a 1-year high of $44.60. The company has a debt-to-equity ratio of 1.57, a current ratio of 9.93 and a quick ratio of 9.93. The business’s fifty day moving average price is $27.74 and its two-hundred day moving average price is $23.63. The firm has a market capitalization of $2.04 billion, a PE ratio of -3.48 and a beta of -1.03.

Zenas BioPharma (NASDAQ:ZBIO) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($1.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.65). The firm had revenue of $1.00 million for the quarter, compared to the consensus estimate of $15.00 million. On average, research analysts expect that Zenas BioPharma, Inc. will post -5.81 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on ZBIO shares. HC Wainwright reissued a “buy” rating on shares of Zenas BioPharma in a research report on Wednesday, June 3rd. Guggenheim reiterated a “buy” rating and set a $55.00 price objective on shares of Zenas BioPharma in a research note on Friday, August 14th. Wedbush reissued an “outperform” rating and set a $45.00 price objective on shares of Zenas BioPharma in a report on Friday, August 14th. Weiss Ratings downgraded shares of Zenas BioPharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 9th. Finally, Zacks Research upgraded shares of Zenas BioPharma from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $45.71.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.